FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation

被引：6

作者：

Blackmon, Amanda ^{[1
]}

Aldoss, Ibrahim ^{[1
]}

Ball, Brian J. ^{[1
,2
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Dept Hematol & HCT, Div Leukemia, 1500 E Duarte Rd, Duarte, CA 91010 USA

来源：

BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY | 2022年 / 12卷

关键词：

FLT3; inhibitor; posttransplantation; maintenance; stem -cell transplantation; midostaurin; sorafenib; ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; MINIMAL RESIDUAL DISEASE; TYROSINE KINASE INHIBITORS; ACUTE MYELOGENOUS LEUKEMIA; PHASE-I; PROGNOSTIC-SIGNIFICANCE; SORAFENIB MAINTENANCE; ALLELIC RATIO; AML;

D O I：

10.2147/BLCTT.S281252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mutations in the FLT3 gene are associated with poor prognosis in patients with AML, even after consolidation with allogeneic hematopoietic cell transplantation (alloHCT) in first remission. Treatment failure in FLT3-mutated AML is largely driven by excessive risk of relapse compared to other genetic subtypes, including in patients post-alloHCT. As a result, there is substantial interest in studying posttransplant maintenance therapy in FLT3-mutated AML as an approach to optimize disease control and improve long-term outcomes. Clinical trials utilizing posttransplant FLT3 inhibitors, such as sorafenib and midostaurin, have shown feasibility, safety, and encouraging posttransplant outcomes, and there are ongoing studies using newer-generation tyrosine-kinase inhibitors as posttransplant maintenance therapy. Here, we review the toxicities and efficacy of FLT3 inhibitors as posttransplant maintenance, recommendations on the use of FLT3 inhibitors by international consensus guidelines, and highlight key remaining questions.

引用

页码：137 / 147

页数：11

共 74 条

[21] Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm [J].

Fröhling, S ;

Schlenk, RF ;

Breitruck, J ;

Benner, A ;

Kreitmeier, S ;

Tobis, K ;

Döhner, H ;

Döhner, K .

BLOOD, 2002, 100 (13) :4372-4380

[22] Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation [J].

Gaballa, Sameh ;

Saliba, Rima ;

Oran, Betul ;

Brammer, Jonathan E. ;

Chen, Julianne ;

Rondon, Gabriela ;

Alousi, Amin M. ;

Kebriaei, Partow ;

Marin, David ;

Popat, Uday R. ;

Andersson, Borje S. ;

Shpall, Elizabeth J. ;

Jabbour, Elias ;

Daver, Naval ;

Andreeff, Michael ;

Ravandi, Farhad ;

Cortes, Jorge ;

Patel, Keyur ;

Champlin, Richard E. ;

Ciurea, Stefan O. .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (04) :331-337

[23] Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial [J].

Ganguly, Siddhartha ;

Cortes, Jorge E. ;

Kraemer, Alwin ;

Levis, Mark J. ;

Martinelli, Giovanni ;

Perl, Alexander E. ;

Russell, Nigel H. ;

Arunachalam, Meena ;

Dos Santos, Cedric ;

Gammon, Guy ;

Lesegretain, Arnaud ;

Mires, Derek E. ;

Pham, Hoang ;

Wang, Yibin ;

Khaled, Samer K. .

TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (02) :153-162

[24] The Development of FLT3 Inhibitors in Acute Myeloid Leukemia [J].

Garcia, Jacqueline S. ;

Stone, Richard M. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (04) :663-+

[25] Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD [J].

Ho, Anthony D. ;

Schetelig, Johannes ;

Bochtler, Tilmann ;

Schaich, Markus ;

Schaefer-Eckart, Kerstin ;

Haenel, Mathias ;

Roesler, Wolf ;

Einsele, Hermann ;

Kaufmann, Martin ;

Serve, Hubert ;

Berde, Wolfgang E. ;

Stelljes, Matthias ;

Mayer, Jiri ;

Reichle, Albrecht ;

Baldus, Claudia D. ;

Schmitz, Norbert ;

Kramer, Michael ;

Roellig, Christoph ;

Bornhaeuser, Martin ;

Thiede, Christian ;

Ehninger, Gerhard .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) :462-469

[26] Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia [J].

Jan, Max ;

Snyder, Thomas M. ;

Corces-Zimmerman, M. Ryan ;

Vyas, Paresh ;

Weissman, Irving L. ;

Quake, Stephen R. ;

Majeti, Ravindra .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (149)

[27] Molecular Minimal Residual Disease in Acute Myeloid Leukemia [J].

Jongen-Lavrencic, M. ;

Grob, T. ;

Hanekamp, D. ;

Kavelaars, F. G. ;

al Hinai, A. ;

Zeilemaker, A. ;

Erpelinck-Verschueren, C. A. J. ;

Gradowska, P. L. ;

Meijer, R. ;

Cloos, J. ;

Biemond, B. J. ;

Graux, C. ;

Kooy, M. van Marwijk ;

Manz, M. G. ;

Pabst, T. ;

Passweg, J. R. ;

Havelange, V. ;

Ossenkoppele, G. J. ;

Sanders, M. A. ;

Schuurhuis, G. J. ;

Lowenberg, B. ;

Valk, P. J. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13) :1189-1199

[28] FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations [J].

Kayser, Sabine ;

Levis, Mark J. .

LEUKEMIA & LYMPHOMA, 2014, 55 (02) :243-255

[29] Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome [J].

Kayser, Sabine ;

Schlenk, Richard F. ;

Londono, Martina Correa ;

Breitenbuecher, Frank ;

Wittke, Kerstin ;

Du, Juan ;

Groner, Silja ;

Spaeth, Daniela ;

Krauter, Juergen ;

Ganser, Arnold ;

Doehner, Hartmut ;

Fischer, Thomas ;

Doehner, Konstanze .

BLOOD, 2009, 114 (12) :2386-2392

[30] Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification [J].

Ke, Yi-Yu ;

Singh, Vivek Kumar ;

Coumar, Mohane Selvaraj ;

Hsu, Yung Chang ;

Wang, Wen-Chieh ;

Song, Jen-Shin ;

Chen, Chun-Hwa ;

Lin, Wen-Hsing ;

Wu, Szu-Huei ;

Hsu, John T. A. ;

Shih, Chuan ;

Hsieh, Hsing-Pang .

SCIENTIFIC REPORTS, 2015, 5

← 1 2 3 4 5 6 7 8 →